This company has been acquired
Semler Scientific (SMLR) Aktievy
Semler Scientific, Inc. tillhandahåller tekniska lösningar för att förbättra den kliniska effektiviteten hos vårdgivare i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
SMLR Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Semler Scientific, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$20.33 |
| 52 veckors högsta | US$65.98 |
| 52 veckors lägsta | US$14.89 |
| Beta | 1.32 |
| 1 månads förändring | 13.39% |
| 3 månaders förändring | -9.76% |
| 1 års förändring | -68.69% |
| 3 års förändring | -45.31% |
| 5 års förändring | -77.41% |
| Förändring sedan börsintroduktionen | 190.84% |
Senaste nyheter och uppdateringar
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.
SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).Recent updates
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).SMLR: All Stock Acquisition Will Unlock Bitcoin Treasury Upside
Analysts have reduced their price target on Semler Scientific to $86 from $101, citing lower revenue and margin forecasts, as well as uncertainty and opportunity created by the recent all stock acquisition agreement and legal settlement. Analyst Commentary Bullish analysts acknowledge the reduced price targets but continue to frame the all stock acquisition and legal settlement as catalysts that could unlock value for Semler Scientific over the medium term.
SMLR: Shares Will Rise As All Stock Acquisition Drives Bitcoin Treasury Consolidation
Analysts have trimmed their average price target for Semler Scientific by about $15 to roughly $83 per share, citing reduced revenue expectations following updated management guidance and the implications of the recent DOJ settlement. They continue to view the stock as an attractive opportunity in light of the pending all stock acquisition by Strive and consolidation prospects in the corporate bitcoin treasury space.SMLR: Shares Will Reflect Upside As $1.4 Billion Acquisition Advances
Analysts have lowered their fair value estimate for Semler Scientific by approximately $10. This change is due to reduced revenue growth projections and updated guidance in light of recent acquisition and settlement developments.Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Analysts have lowered their price target for Semler Scientific from $85.33 to $75.33, citing reduced revenue forecasts following cautious management guidance, weighing of recent legal settlements, and uncertainty around the company’s pivot to a bitcoin treasury strategy despite some bullish views on its potential long-term re-rating. Analyst Commentary Bullish analysts see the acquisition by Strive (ASST) as triggering potential consolidation in the corporate bitcoin treasury sector, presenting a timely opportunity despite market uncertainty around the transaction’s longer-term implications.Is Semler Scientific (NASDAQ:SMLR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Diversification into cardiac disease markets and value-based care tools positions the company for higher recurring revenues and improved long-term margins.Semler Scientific, Inc.'s (NASDAQ:SMLR) 26% Share Price Surge Not Quite Adding Up
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have had a really impressive month, gaining 26% after a shaky period...Semler Scientific: Not The Ideal Bitcoin Treasury Company
Summary Semler Scientific's pivot to a Bitcoin treasury strategy has been successful. However, competition in the Bitcoin Treasury company space is heating up, including many well funded competitors. Declining revenues and free cash flow in its healthcare business are concerning, and Bitcoin is materially outperforming the Company year to date. Read the full article on Seeking AlphaSemler Scientific, Inc.'s (NASDAQ:SMLR) 32% Price Boost Is Out Of Tune With Revenues
Semler Scientific, Inc. ( NASDAQ:SMLR ) shareholders are no doubt pleased to see that the share price has bounced 32...Here's Why We Think Semler Scientific (NASDAQ:SMLR) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Semler Scientific's (NASDAQ:SMLR) Profits May Not Reveal Underlying Issues
The recent earnings posted by Semler Scientific, Inc. ( NASDAQ:SMLR ) were solid, but the stock didn't move as much as...Semler Scientific, Inc. (NASDAQ:SMLR) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Semler Scientific, Inc. ( NASDAQ:SMLR ) share price has dived 25% in the last...Semler Scientific, Inc. (NASDAQ:SMLR) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have retraced a considerable 26% in the last month, reversing a fair...Aktieägarnas avkastning
| SMLR | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -0.05% | 5.7% | -0.7% |
| 1Y | -68.7% | -17.8% | 20.3% |
Avkastning vs industri: SMLR presterade sämre än US Medical Equipment branschen som gav -17.8 % under det senaste året.
Avkastning vs Marknaden: SMLR presterade sämre än US marknaden som gav 20.3 % under det senaste året.
Prisvolatilitet
| SMLR volatility | |
|---|---|
| SMLR Average Weekly Movement | 18.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: SMLR s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SMLR s veckovolatilitet ( 19% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2007 | 79 | Doug Murphy-Chutorian | www.semlerscientific.com |
Semler Scientific, Inc. tillhandahåller tekniska lösningar för att förbättra den kliniska effektiviteten och effektiviteten hos vårdgivare i USA. Bolagets produkter inkluderar QuantaFlo, ett fyra minuter långt blodflödestest som utförs på kontoret och som gör det möjligt för vårdgivare att använda blodflödesmätningar som en del av sina undersökningar av en patients kärltillstånd. Bolagets produkter riktar sig till kardiologer, internmedicinare, nefrologer, endokrinologer, podiatriker, allmänläkare, sjukvårdsförsäkringar, integrerade leveransnätverk, oberoende läkargrupper och företag som arbetar med sjukvårdsindustrin, t.ex. riskbedömningsgrupper och återförsäljare.
Semler Scientific, Inc. Sammanfattning av grunderna
| SMLR grundläggande statistik | |
|---|---|
| Börsvärde | US$310.75m |
| Vinst(TTM) | US$48.34m |
| Intäkter(TTM) | US$36.96m |
Är SMLR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SMLR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$36.96m |
| Kostnad för intäkter | US$3.41m |
| Bruttovinst | US$33.54m |
| Övriga kostnader | -US$14.80m |
| Intäkter | US$48.34m |
Senast redovisade vinst
Sep 30, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 3.16 |
| Bruttomarginal | 90.76% |
| Nettovinstmarginal | 130.80% |
| Skuld/egenkapitalförhållande | 25.3% |
Hur har SMLR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/01/20 08:01 |
| Aktiekurs vid dagens slut | 2026/01/15 00:00 |
| Intäkter | 2025/09/30 |
| Årlig intjäning | 2024/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Semler Scientific, Inc. bevakas av 3 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Mark Palmer | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Brett Knoblauch | Cantor Fitzgerald & Co. |